BioCentury | Apr 20, 1998
Company News

Aquila, VacTex deal

...AQLA acquired VacTex, a tuberculosis vaccine developer, for 1.15 million AQLA common shares and a $1.3...
...AQLA common shares and a $1.3 million, 7 percent note redeemable after April 13, 1999. VacTex's...
...account for the acquisition. (AQLA appointments, B6 and B7) Aquila Biopharmaceuticals Inc. (AQLA), Worcester, Mass. VacTex Inc....
BioCentury | Apr 20, 1998
Company News

Aquila board of directors update

...Autoimmune/Inflammation, Cancer, Infectious diseases Appointed: Robert Carpenter, chairman and president of VacTex Inc. (AQLA's SAB, below; VacTex...
BioCentury | Apr 20, 1998
Company News

Aquila scientific advisory board update

...AQLA board appointment, B6; VacTex acquisition, B3) Aquila Biopharmaceuticals Inc. (AQLA), Worcester, Mass. Business: Autoimmune/Inflammation, Cancer...
BioCentury | Aug 4, 1997
Company News

Procept other research news

...Boston, who are collaborators on the SBIR grant. PRCT and investors have founded a company, VacTex...
BioCentury | Sep 16, 1996
Company News

Procept infectious diseases/aids, autoimmune/inflammation news

...PRCT is restructuring to focus on its internal HIV program and its VacTex Inc. affiliate's drug development...
...will seek a partner for its two immunosuppression programs. PRCT has a minority interest in VacTex...
BioCentury | Jan 15, 1996
Strategy

Baxter's busy alumni network

...antigen presentation, but the company didn't want to increase its burn rate. The result was VacTex...
...charter is to provide seed money." VacTex is Boston Medical's first investment. The technology behind VacTex...
...PRCT (Cambridge, Mass.) always has been involved in T cell biology and antigen presentation. The VacTex...
Items per page:
1 - 6 of 6
BioCentury | Apr 20, 1998
Company News

Aquila, VacTex deal

...AQLA acquired VacTex, a tuberculosis vaccine developer, for 1.15 million AQLA common shares and a $1.3...
...AQLA common shares and a $1.3 million, 7 percent note redeemable after April 13, 1999. VacTex's...
...account for the acquisition. (AQLA appointments, B6 and B7) Aquila Biopharmaceuticals Inc. (AQLA), Worcester, Mass. VacTex Inc....
BioCentury | Apr 20, 1998
Company News

Aquila board of directors update

...Autoimmune/Inflammation, Cancer, Infectious diseases Appointed: Robert Carpenter, chairman and president of VacTex Inc. (AQLA's SAB, below; VacTex...
BioCentury | Apr 20, 1998
Company News

Aquila scientific advisory board update

...AQLA board appointment, B6; VacTex acquisition, B3) Aquila Biopharmaceuticals Inc. (AQLA), Worcester, Mass. Business: Autoimmune/Inflammation, Cancer...
BioCentury | Aug 4, 1997
Company News

Procept other research news

...Boston, who are collaborators on the SBIR grant. PRCT and investors have founded a company, VacTex...
BioCentury | Sep 16, 1996
Company News

Procept infectious diseases/aids, autoimmune/inflammation news

...PRCT is restructuring to focus on its internal HIV program and its VacTex Inc. affiliate's drug development...
...will seek a partner for its two immunosuppression programs. PRCT has a minority interest in VacTex...
BioCentury | Jan 15, 1996
Strategy

Baxter's busy alumni network

...antigen presentation, but the company didn't want to increase its burn rate. The result was VacTex...
...charter is to provide seed money." VacTex is Boston Medical's first investment. The technology behind VacTex...
...PRCT (Cambridge, Mass.) always has been involved in T cell biology and antigen presentation. The VacTex...
Items per page:
1 - 6 of 6